GenSight Biologics (GSGTF) News Today $0.32 0.00 (0.00%) (As of 10/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business UpdatesSeptember 25, 2024 | finance.yahoo.comGenSight Biologics Launches Newsletter for Retail InvestorsJuly 11, 2024 | businesswire.comGenSight Biologics Appoints William Monteith to its Board of DirectorsJune 3, 2024 | businesswire.comGenSight Biologics Announces the Availability of a Prospectus in Connection With the Listing of New Shares on Euronext ParisMay 7, 2024 | finance.yahoo.comGenSight Biologics: Annual General Meeting on May 29, 2024May 7, 2024 | businesswire.comGenSight Biologics Announces a Successful Offering for an Amount Over €9.2 MillionMay 7, 2024 | finance.yahoo.comGenSight Biologics Announces the Filing of its 2023 Universal Registration DocumentApril 18, 2024 | businesswire.comGenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business UpdateApril 4, 2024 | businesswire.comGenSight Biologics Reports Full Year 2023 Consolidated Financial ResultsMarch 22, 2024 | finance.yahoo.comGenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time AdministrationMarch 20, 2024 | finance.yahoo.comGenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024March 6, 2024 | finance.yahoo.comGenSight Biologics S.A. (GSGTF)February 16, 2024 | finance.yahoo.comGenSight Biologics announces completion of a €5 million capital increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights CapitalFebruary 8, 2024 | finance.yahoo.comGenSight Biologics Reports Cash Position as of December 31, 2023, and Provides Business UpdateJanuary 25, 2024 | finance.yahoo.comLaurence Rodriguez, Appointed CEO of GenSight Biologics in December 2023, Joins the Company’s Board of DirectorsJanuary 16, 2024 | finance.yahoo.comGenSight Biologics Provides Business and Financial UpdateDecember 27, 2023 | finance.yahoo.comGenSight Biologics appoints Laurence Rodriguez as Chief Executive OfficerDecember 22, 2023 | finance.yahoo.comBiologicsNovember 23, 2023 | seekingalpha.comGensight Biologics SA SIGHTNovember 22, 2023 | morningstar.comGenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ® and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 millionNovember 15, 2023 | finance.yahoo.comGenSight Biologics Reports Cash Position as of September 30, 2023, and Provides Business UpdateOctober 26, 2023 | finance.yahoo.comGenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ®September 27, 2023 | finance.yahoo.comGenSight Biologics Announces Successful Manufacture of LUMEVOQ® GMP BatchSeptember 18, 2023 | finance.yahoo.comGenSight Biologics Reports Interim Financial Results for the First Half of 2023September 15, 2023 | finance.yahoo.comUFO whistleblower alleges 'non-human' biologics found at crash sitesJuly 30, 2023 | nbcnews.comGenSight Biologics Provides Financial and Operational UpdateJuly 20, 2023 | finance.yahoo.comGenSight Biologics Announces the Filing of its 2022 Universal Registration Document and Reschedules its Annual General Meeting on June 21, 2023May 10, 2023 | finance.yahoo.comGenSight Biologics S.A.May 2, 2023 | wsj.comGenSight Biologics Announces the Re-approval of its Full Year 2022 Consolidated Financial StatementsMay 1, 2023 | finance.yahoo.comGenSight Biologics Withdraws its EMA Application for LUMEVOQ®April 20, 2023 | finance.yahoo.comGenSight Biologics Reports Cash Position as of March 31, 2023, and Provides Business UpdateApril 20, 2023 | finance.yahoo.comGenSight Biologics to Host a Webcast on April 5, 2023, to Provide an Update on LUMEVOQ® Manufacturing Following Investigations FindingsApril 4, 2023 | finance.yahoo.comGenSight Biologics Reports Full Year 2022 Consolidated Financial ResultsMarch 24, 2023 | finance.yahoo.comGenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023March 15, 2023 | finance.yahoo.comGenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III TrialMarch 13, 2023 | finance.yahoo.comGenSight Biologics to Present at Upcoming Medical ConferencesMarch 10, 2023 | finance.yahoo.comGenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of OphthalmologyMarch 9, 2023 | finance.yahoo.comGenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization TimelinesMarch 7, 2023 | finance.yahoo.comGenSight Biologics Announces its 2023 Financial CalendarMarch 1, 2023 | finance.yahoo.comRare Disease Day 2023: GenSight Biologics Raises Awareness of Leber Hereditary Optic Neuropathy (LHON)February 28, 2023 | finance.yahoo.comBiologics Development and Manufacturing Testing Technologies and Global Market Research Report 2023February 25, 2023 | benzinga.comGenSight Biologics Announces the Drawdown of the First EUR 8 Million Tranche Under Its Credit Agreement With the European Investment BankFebruary 6, 2023 | finance.yahoo.comGenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business UpdateJanuary 26, 2023 | finance.yahoo.comTheriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology ConferenceJanuary 25, 2023 | finance.yahoo.comGenSight Biologics to Present at Upcoming Investor ConferencesJanuary 4, 2023 | finance.yahoo.comGenSight Biologics Secures €12 Million Financing Through a Premium Convertible Notes Issuance to an Institutional Investor and Provides Business UpdateDecember 23, 2022 | finance.yahoo.comGenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and TherapyDecember 15, 2022 | finance.yahoo.comGenSight Biologics Announces Publication of Results of LUMEVOQ® REFLECT Pivotal Clinical Trial in Peer-Reviewed JournalsNovember 17, 2022 | finance.yahoo.comGenSight Biologics Secures a €35 Million Credit Facility From the European Investment Bank to Support the Launch of LUMEVOQ® in EuropeNovember 4, 2022 | finance.yahoo.comGenSight Biologics Reports Cash Position and Revenues as of September 30, 2022October 28, 2022 | finance.yahoo.com Get GenSight Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for GSGTF and its competitors with MarketBeat's FREE daily newsletter. Email Address Next opportunity for crypto millions (Ad)The floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since they first opened to investors. Wall Street is finally embracing crypto. But most investors are missing the real goldmine… Go here to discover the crypto that's about to leave Wall Street in the dust. GSGTF Media Mentions By Week GSGTF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GSGTF News Sentiment▼0.000.56▲Average Medical News Sentiment GSGTF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GSGTF Articles This Week▼00▲GSGTF Articles Average Week Get GenSight Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for GSGTF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Algernon Pharmaceuticals News ALK-Abelló A/S News Alpha Tau Medical News Arno Therapeutics News Ascentage Pharma Group International News Ascletis Pharma News Avacta Group News Awakn Life Sciences News AXIM Biotechnologies News BerGenBio ASA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GSGTF) was last updated on 10/4/2024 by MarketBeat.com Staff From Our Partners$20 = Ounce of Gold?I've discovered a way to get exposure to MORE than an ounce of gold... for under $20. It's not bullion. It'...Monument Traders Alliance | SponsoredThe world’s smartest man is in their crosshairsElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GenSight Biologics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share GenSight Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
